Pas de connexion internet — affichage de la version enregistrée de la page.

Innate Pharma

FREUR
← Vers le Screener

Innate Pharma (LSE:0EVI) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
innate-pharma.com
Secteur
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siège Social
MARSEILLE, France
PDG
Jonathan E. Dickinson
Employés
120
Fondée
1999
Actions en Circulation
111.7 M
Flottant
70.45 M
Capitalisation Boursière
146.33 M EUR
Initiés
17.46%
Investisseurs Institutionnels
10.86%
Secteur d'Activité (SIC)
Biological Products, (No Diagnostic Substances)
Forme Juridique
K65D
ISIN
FR0010331421
LEI
9695002Y8420ZB8HJE29
P/E
perte
FCF
−52.9 M EUR
Dette
?
Résultats et FCF — pour les 12 mois à 31.12.2025 (dernier rapport de l'entreprise).
Description

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
PA Euronext ParisIPH principaleEUR1.302 +0.62%actions ordinaires
LSE London Stock Exchange0EVI IOBEUR1.304 +2.27%actions ordinaires
US USA StocksIPHYF OTCUSD1.5092 -8.53%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30